Comparing the efficacy of sodium valproate and levetiracetam following initial lorazepam in elderly patients with generalized convulsive status epilepticus (GCSE): A prospective randomized controlled pilot study

التفاصيل البيبلوغرافية
العنوان: Comparing the efficacy of sodium valproate and levetiracetam following initial lorazepam in elderly patients with generalized convulsive status epilepticus (GCSE): A prospective randomized controlled pilot study
المؤلفون: Parayil Sankaran Bindu, Rose Dawn Bharath, Kandavel Thennarasu, Madhu Nagappa, Kenchaiah Raghavendra, Arun B Taly, Parthasarathy Satishchandra, Parthipulli Vasuki Prathyusha, Ravindranadh Chowdary Mundlamuri, Jitender Saini, Sanjib Sinha, Devavrat Nene
المصدر: Seizure. 65:111-117
بيانات النشر: Elsevier BV, 2019.
سنة النشر: 2019
مصطلحات موضوعية: Male, Aging, Levetiracetam, Pilot Projects, Lorazepam, law.invention, 03 medical and health sciences, Epilepsy, Status Epilepticus, 0302 clinical medicine, Randomized controlled trial, law, Elderly population, Seizure control, medicine, Humans, Single-Blind Method, Prospective Studies, Aged, Aged, 80 and over, Dose-Response Relationship, Drug, Convulsive status epilepticus, business.industry, Valproic Acid, Electroencephalography, Mean age, General Medicine, Middle Aged, medicine.disease, Logistic Models, Treatment Outcome, Neurology, Anesthesia, Anticonvulsants, Female, Neurology (clinical), business, 030217 neurology & neurosurgery, medicine.drug
الوصف: Purpose: This randomized control study was conducted to compare the efficacy of sodium valproate (SVP) and levetiracetam (LEV) following initial intravenous lorazepam in elderly patients (age: >60years) with generalized convulsive status epilepticus (GCSE) and to identify predictors of poor seizure control. Methods: A total of 118 patients (mean age: 67.5 ± 7.5 years, M:F = 1.6:1), who had presented with GCSE were randomized into the SVP or LEV treatment arms. All patients received initial intravenous lorazepam (0.1 mg/kg) followed by one of the two antiepileptic drugs (AEDs), parenteral SVP (20–25 mg/kg) or LEV (20–25 mg/kg). Those who failed to achieve control with the initial AED, were crossed over to receive the other AED. One-hundred patients (SVP = 50; LEV = 50) completed the study. Results: SE could be controlled with lorazepam and one of the AEDs (SVP or LEV) in 71.18% (84/118). Intention-to-treat analysis showed that the two groups did not differ significantly in terms of seizure control [SVP: 41/60 (68.3%); LEV: 43/58 (74.1%), p = 0.486]. Of 100 patients who completed the study, seizure control was achieved in 38/50(76%) in the SVP and 43/50(86%) in the LEV group (p = 0.202). After crossing over to the second AED, SE could be controlled in an additional in 50% (6/12) in SVP (+LEV) group and in 14.3% (1/7) in LEV (+SVP) group. Overall, after the second AED, seizure control was achieved in 77.1% (91/118). Higher STESS was associated with poor therapeutic response (p = 0.049). Conclusions: The efficacy of SVP and LEV following initial lorazepam in controlling GCSE in elderly population was comparable, hence the choice of AED could be individualized.
تدمد: 1059-1311
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16aa535837197f7c6cbbb7658369c718Test
https://doi.org/10.1016/j.seizure.2019.01.015Test
حقوق: OPEN
رقم الانضمام: edsair.doi.dedup.....16aa535837197f7c6cbbb7658369c718
قاعدة البيانات: OpenAIRE